First Author: L.Okafor UK
Co Author(s): S. Mukhopadhyay A. Gurung A. Smith
Back to previous
A retrospective review of the relative efficacy of sub-threshold micropulse diode laser versus conventional laser versus ranibizumab for the treatment of diabetic macula oedema.
All patients were selected from Hereford Eye Unit macula clinic.
A total of 83 eyes were identified over a 6-month period and a retrospective review of the case notes took place. The first 30 eyes receiving micropulse laser, 23 eyes receiving conventional laser and 30 eyes receiving ranibizumab were selected. Specifically, primary outcomes and efficacy estimates were determined by comparing best corrected visual acuity (BCVA), central macula thickness (CMT) and macula volume.
As expected ranibizumab showed superiority to both laser groups. All groups showed reduction in central macula thickness though only ranibizumab was found to be significant (-133m; p < 0.05). Sub-threshold macula laser was equally as efficacious as conventional laser at 6 months in terms of mean change in LogMAR BCVA. In addition there was no significant difference found between the two laser groups in terms of mean change in CMT (-6.4 m; p=0.45).
ranibizumab is superior to both sub-threshold macula laser and conventional laser. Most importantly sub-threshold macula laser is equally effective as conventional laser in terms of change in BCVA and central macula thickness. Both treatments have similar anatomical outcomes.